Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome
Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome: A Randomized Clinical Trial
October 6 University
60 participants
Nov 25, 2023
INTERVENTIONAL
Conditions
Summary
Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet and physical activity that are the first-line approach to treatment; however, they are reported to be minimally effective in reducing weight or treating PCOS-related symptoms.Pharmacological options are also available; however, they are not explicitly approved for PCOS treatment as they have been primarily used to treat other conditions such as T2DM
Eligibility
Inclusion Criteria1
- Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of Health criteria.
Exclusion Criteria4
- Patients with history of diabetes mellitus (Type 1 or 2).
- Patients with liver or renal dysfunction; inflammatory diseases; autoimmune disease; cancer, acute cardiovascular event within last three months
- Known hypersensitivity or contraindications to use dipeptidyl peptidase-4 (DPP-4) inhibitors
- Eating disorders (anorexia, bulimia) or gastrointestinal disorders
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Metformin Hydrochloride 850 mg oral tablet
Vildagliptin 50 MG oral tablets
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06142656